NCT06241326 Immunotherapy for Hepatocellular Carcinoma
| NCT ID | NCT06241326 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 11,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 11,000 participants in total. It began in 2024-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
Eligibility Criteria
Inclusion Criteria: 1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study. Exclusion Criteria: 1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06241326 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06241326 currently recruiting?
Yes, NCT06241326 is actively recruiting participants. Contact the research team at mxrlwx19911990@163.com for enrollment information.
Where is the NCT06241326 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06241326 clinical trial?
NCT06241326 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 11,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.